[
  {
    "ts": null,
    "headline": "Amgen: Riding The MariTide Of Monthly Weight Loss",
    "summary": "Amgen stock rose 13% as obesity drug MariTide advances. Click here to find out why AMGN stock is a Buy.",
    "url": "https://finnhub.io/api/news?id=3ec2b5102da8b330ae6a137f5e4d951e50cb5c459820cacda196d8a84ae9be96",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741625200,
      "headline": "Amgen: Riding The MariTide Of Monthly Weight Loss",
      "id": 133127786,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1220400589/image_1220400589.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Amgen stock rose 13% as obesity drug MariTide advances. Click here to find out why AMGN stock is a Buy.",
      "url": "https://finnhub.io/api/news?id=3ec2b5102da8b330ae6a137f5e4d951e50cb5c459820cacda196d8a84ae9be96"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: CagriSema Disappoints Again",
    "summary": "Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, and stay competitive. Click for more.",
    "url": "https://finnhub.io/api/news?id=0a93f2015f1580d5dfe39a873aa02c717da2e058d2167fb48ae6257e0bbdc20c",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741611136,
      "headline": "Novo Nordisk: CagriSema Disappoints Again",
      "id": 133122220,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2160633003/image_2160633003.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, and stay competitive. Click for more.",
      "url": "https://finnhub.io/api/news?id=0a93f2015f1580d5dfe39a873aa02c717da2e058d2167fb48ae6257e0bbdc20c"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study",
    "summary": "INDIANAPOLIS - Late-breaking results from Eli Lilly and Company and Incyte found adolescent patients with severe alopecia areata treated with once-daily, oral baricitinib 4 mg and 2 mg saw...",
    "url": "https://finnhub.io/api/news?id=e6daed9e467c15a08293b7e8ca356e870bfd1ad21d4e8f5115ec2436c9ad1d37",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741610360,
      "headline": "Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study",
      "id": 133122066,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "INDIANAPOLIS - Late-breaking results from Eli Lilly and Company and Incyte found adolescent patients with severe alopecia areata treated with once-daily, oral baricitinib 4 mg and 2 mg saw...",
      "url": "https://finnhub.io/api/news?id=e6daed9e467c15a08293b7e8ca356e870bfd1ad21d4e8f5115ec2436c9ad1d37"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's EBGLYSS single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis",
    "summary": "INDIANAPOLIS - New results show Eli Lilly and Company's EBGLYSS achieved deep and sustained response for patients with moderate-to-severe atopic dermatitis at three years.These findings from the...",
    "url": "https://finnhub.io/api/news?id=5a6e8ad2c07fff6da8f1aeac8700a28704415635b2dfa472ed8a0d0aab137936",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741610242,
      "headline": "Lilly's EBGLYSS single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis",
      "id": 133122030,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "INDIANAPOLIS - New results show Eli Lilly and Company's EBGLYSS achieved deep and sustained response for patients with moderate-to-severe atopic dermatitis at three years.These findings from the...",
      "url": "https://finnhub.io/api/news?id=5a6e8ad2c07fff6da8f1aeac8700a28704415635b2dfa472ed8a0d0aab137936"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) Management presents at Leerink 2025 Global Healthcare Conference (Transcript)",
    "summary": "Eli Lilly and Company (NYSE:LLY) Leerink 2025 Global Healthcare Conference March 10, 2025 9:20 AM ETCompany ParticipantsLucas Montarce - CFOMike Czapar -...",
    "url": "https://finnhub.io/api/news?id=57ecc209f8fb43719554e558ca22bcade96957702f91606ca775f69af57c4e02",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741607262,
      "headline": "Eli Lilly and Company (LLY) Management presents at Leerink 2025 Global Healthcare Conference (Transcript)",
      "id": 133121766,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly and Company (NYSE:LLY) Leerink 2025 Global Healthcare Conference March 10, 2025 9:20 AM ETCompany ParticipantsLucas Montarce - CFOMike Czapar -...",
      "url": "https://finnhub.io/api/news?id=57ecc209f8fb43719554e558ca22bcade96957702f91606ca775f69af57c4e02"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Stock Drops on New Obesity Drug Findings. Eli Lilly Stands to Gain.",
    "summary": "Novo Nordisk Stock Drops on New Obesity Drug Findings. Eli Lilly Stands to Gain.",
    "url": "https://finnhub.io/api/news?id=7b0eb625771605b51193f49c6b35a8d4e475174362a428ed4789007eaca70d5d",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741602660,
      "headline": "Novo Nordisk Stock Drops on New Obesity Drug Findings. Eli Lilly Stands to Gain.",
      "id": 133118273,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Novo Nordisk Stock Drops on New Obesity Drug Findings. Eli Lilly Stands to Gain.",
      "url": "https://finnhub.io/api/news?id=7b0eb625771605b51193f49c6b35a8d4e475174362a428ed4789007eaca70d5d"
    }
  },
  {
    "ts": null,
    "headline": "Here’s why Ozempic maker’s new weight-loss drug isn’t good enough for investors",
    "summary": "Here’s why Ozempic maker’s new weight-loss drug isn’t good enough for investors",
    "url": "https://finnhub.io/api/news?id=3c300030d4def6d567b2a264b9f3aefe47dfaa3ef0cac8a1f28d8b212e2d77fe",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741600680,
      "headline": "Here’s why Ozempic maker’s new weight-loss drug isn’t good enough for investors",
      "id": 133118274,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Here’s why Ozempic maker’s new weight-loss drug isn’t good enough for investors",
      "url": "https://finnhub.io/api/news?id=3c300030d4def6d567b2a264b9f3aefe47dfaa3ef0cac8a1f28d8b212e2d77fe"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly plans to launch Mounjaro in China, India, Brazil and Mexico by 2026, CFO says",
    "summary": "Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, Chief Financial Officer Lucas Montarce said on Monday at the Leerink...",
    "url": "https://finnhub.io/api/news?id=07e5b37328c6969562b4c4526729c59e9b85429096bac745a66332499b31b3a0",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741600389,
      "headline": "Eli Lilly plans to launch Mounjaro in China, India, Brazil and Mexico by 2026, CFO says",
      "id": 133117555,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "Eli Lilly plans to launch Mounjaro, its blockbuster diabetes drug, in countries like China, India, Brazil and Mexico by 2026, Chief Financial Officer Lucas Montarce said on Monday at the Leerink...",
      "url": "https://finnhub.io/api/news?id=07e5b37328c6969562b4c4526729c59e9b85429096bac745a66332499b31b3a0"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk Dives 8%. Why Eli Lilly Now Has The Upper Hand.",
    "summary": "Novo Nordisk Dives 8%. Why Eli Lilly Now Has The Upper Hand.",
    "url": "https://finnhub.io/api/news?id=092b0cf6be2f890ab65f0d777ec1087a4204c169d2ba7555a5f4cfd7e415dae2",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741597579,
      "headline": "Novo Nordisk Dives 8%. Why Eli Lilly Now Has The Upper Hand.",
      "id": 133118253,
      "image": "",
      "related": "LLY",
      "source": "DowJones",
      "summary": "Novo Nordisk Dives 8%. Why Eli Lilly Now Has The Upper Hand.",
      "url": "https://finnhub.io/api/news?id=092b0cf6be2f890ab65f0d777ec1087a4204c169d2ba7555a5f4cfd7e415dae2"
    }
  }
]